NEW HIGHLIGHT
Vizimpro

Vizimpro

dacomitinib

Manufacturer:

Pfizer

Distributor:

Zuellig Pharma

Marketer:

Pfizer
Concise Prescribing Info
Contents
Dacomitinib
Indications/Uses
1st-line treatment in adults w/ locally advanced or metastatic non-small cell lung cancer (NSCLC) w/ epidermal growth factor receptor (EGFR)-activating mutations.
Dosage/Direction for Use
45 mg once daily until disease progressions or unacceptable toxicity occurs. Recommended dose modification for adverse reactions 1st dose reduction: 30 mg once daily. 2nd dose reduction: 15 mg once daily.
Administration
May be taken with or without food: Take at the same time each day.
Contraindications
Special Precautions
Discontinue use if interstitial lung disease/pneumonitis occurs. Diarrhea; rash, erythematous & exfoliative skin conditions. Increased hepatotoxicity & transaminases. Limit sun exposure. Galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption. Concomitant use of medicinal products metabolised by CYP2D6. Avoid concomitant use w/ proton-pump inhibitors. May affect ability to drive & use machines. Severe hepatic & renal impairment; patients requiring haemodialysis. Women of childbearing potential should use effective contraception during & at least 17 days after last dose. Not to be used during pregnancy. Lactation. Paed <18 yr.
Adverse Reactions
Decreased appetite, hypokalaemia; conjunctivitis; diarrhoea, stomatitis, vomiting, nausea; rash, palmar-plantar erythrodysaesthesia syndrome, skin fissures, dry skin, pruritus, nail disorder, alopecia; fatigue, asthenia; increased transaminase, decreased wt. Dehydration; dysgeusia; keratitis; interstitial lung disease; skin exfoliation, hypertrichosis.
Drug Interactions
Decreased Cmax, AUC0-96h & AUCinf w/ rabeprazole. Concomitant use w/ proton pump inhibitors. Increased mean exposure of dextromethorphan. Co-administration w/ strong CYP2D6 inhibitors. Inhibited P-glycoprotein activity, breast cancer resistance protein (BCRP) & cation transporter.
ATC Classification
L01EB07 - dacomitinib ; Belongs to the class of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Used in the treatment of cancer.
Presentation/Packing
Form
Vizimpro FC tab 15 mg
Packing/Price
3 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in